Clinicians and researchers have the ability to uncover mysteries in the eye
The eye promises to be a window into the health of a patient. Images of the human retina, an extension of the brain, allows clinicians to make a more precise assessment through a wider view of the retina, important for patients with diseases such as glaucoma, diabetes or age-related macular degeneration (AMD).
Our products push the boundaries of retinal imaging
Clinicians and researchers require new technologies to help them see in the eye at the cellular-level.
Adaptive optics solves this blurriness problem by correcting for these imperfections at a microscopic level and allows for high-resolution imaging of photoreceptor cells. We can do this via an Adaptive Optics Scanning Laser Ophthalmoscope (AOSLO).
AOSLO imaging has the potential to replace or augment less direct methods of tracking disease state such as visual acuity (VA) and can resolve retinal structures and pathology that may be valuable in both diagnosis and treatment.
Apaeros™ Retinal Imaging System
A detailed retinal image of photoreceptor cells with adaptive optics technology with greater than 2 µm resolution.
Boston MicroMachines' cutting-edge retinal imaging system is custom-built to your needs. The Apaeros™ Retinal Imaging System provides cellular resolution for in vivo imaging in the human retina for research studies.
By actively correcting for wavefront aberrations in the optical path between the detector and the retina, our adaptive optics solution is an enabling technology for retinal imaging with cellular-level resolution.
The Apaeros™ Retinal Imaging System's lateral resolution of ~2µm enables in vivo high-resolution imaging of previously imperceptible retinal structures.
Let’s work together to advance eye disease detection and prevention.
We believe you should be able to accurately diagnose and treat disease before the loss of sight begins. In addition, our system can help researchers test drugs for efficacy at the cellular-level. For more information, contact us today.